The partnership will include $105m upfront to Orionis, with the potential for further payments that could exceed $2bn.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the ...

Roche (RHHBF) unit Genentech partners Orionis Biosciences to develop and commercialize cancer drugs in a deal that exceed $2B ...

Privately-held US genome-scale drug discovery company Orionis Biosciences has announced a second multi-year collaboration ...

Orionis Biosciences Inc. is sticking with Genentech Inc. in a second deal to discover small-molecule monovalent glue therapies for treating cancer. Privately held Orionis is getting $105 million up ...

As demand grows for flexible, high-quality addiction treatment, Plugged In Recovery has launched a new outpatient program that expands its continuum of care while preserving the clinical depth and ...

Diabetic retinopathy affects almost 10 million people in the US and is the third FDA-approved indication for Susvimo, which ...

Vaccines and ongoing vigilance are critical to prevent and manage infections in patients who are immunosuppressed or ...

The Primex Family of Companies (PFOC), with its multiple divisions leading the automated monitoring, time, and weather spaces, is pleased to announce the appointment of Joseph Melika to its Board of ...

Hayek, for instance, “trained at home as a botanist to a quasi-professional level; he then graduated in law, received a ...

As reported late last year, the AQUILA trial showed that treatment with daratumumab reduced the risk of progression to ...